{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:50:35Z","timestamp":1740135035102,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Gemcitabine\/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal adenocarcinoma (PDAC). Development of skin rash has been associated with favorable outcomes in patients treated with gemcitabine\/erlotinib. This study aimed to extend knowledge on the effectiveness of gemcitabine\/erlotinib in metastatic PDAC in the context of clinical practice and with focus on skin rash.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This multicenter, non-interventional study enrolled 376 patients with metastatic PDAC receiving gemcitabine\/erlotinib. The primary endpoint was overall survival (OS) in patients with skin rash versus no skin rash. Secondary endpoints included progression-free survival (PFS), treatment satisfaction and safety. All data were analyzed using descriptive statistics. Survival time and time to disease progression were estimated using the Kaplan-Meier method. Effectiveness endpoints were analyzed for subgroups by skin rash grade (no rash, rash grade 1, rash grade\u2009\u2265\u20092), duration of erlotinib treatment (\u22648\u2009weeks, &gt;\u20098\u2009weeks), Eastern Cooperative Oncology Group (ECOG) performance status at baseline (0\u20131, 2) and age (\u226465\u2009years, &gt;\u200965\u2009years).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Within the full analysis set (FAS; <jats:italic>N<\/jats:italic>\u2009=\u2009270), 48 patients (17.8%) developed grade 1 rash, 51 patients (18.9%) grade\u2009\u2265\u20092 rash, while 171 patients (63.3%) did not develop a rash. Median OS of all patients was 9.11\u2009months with an OS of 9.93\u2009months in rash-positive and 8.68\u2009months in rash-negative patients. Median PFS was 5.06\u2009months for rash-positive and 4.11\u2009months for rash-negative patients. PFS was longer in patients with rash grade\u2009\u2265\u20092 and in older patients (&gt;\u200965\u2009years). Examination using a multivariate Cox proportional model revealed that an age\u2009&gt;\u200965\u2009years was associated with longer OS (hazard ratio 0.640; <jats:italic>p<\/jats:italic>\u2009=\u20090.0327) and PFS (hazard ratio 0.642; <jats:italic>p<\/jats:italic>\u2009=\u20090.0026). Out of the 338 patients in the SAF, 310 patients (91.7%) experienced at least one AE, and 176 patients (52.1%) experienced skin-related side effects, all of which were CTC grade 1 to 3.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Comparing rash-positive with rash-negative patients showed no significant difference in survival. While patients with rash grade\u2009\u2265\u20092 and older patients (independent of skin reactions) showed longer PFS, this did not translate into prolonged OS. The study did not reveal new safety signals.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01782690\">NCT01782690<\/jats:ext-link>, retrospectively registered on 4 February 2013.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-6636-7","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T15:06:52Z","timestamp":1582556812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib \u2013 results from a non-interventional multi-center study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-3754","authenticated-orcid":false,"given":"C. Benedikt","family":"Westphalen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Kukiolka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Garlipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"K\u00fctting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Beringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk T.","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"issue":"7","key":"6636_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-16-2319","volume":"23","author":"GA Manji","year":"2017","unstructured":"Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res. 2017;23(7):1670\u20138.","journal-title":"Clin Cancer Res"},{"issue":"10039","key":"6636_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73\u201385.","journal-title":"Lancet"},{"issue":"11","key":"6636_CR3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"9","key":"6636_CR4","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/cam4.767","volume":"5","author":"AS Quante","year":"2016","unstructured":"Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649\u201356.","journal-title":"Cancer Med"},{"issue":"6","key":"6636_CR5","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403\u201313.","journal-title":"J Clin Oncol"},{"issue":"4","key":"6636_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Ther Adv Gastroenterol. 2013;6(4):321\u201337.","journal-title":"Ther Adv Gastroenterol"},{"issue":"15","key":"6636_CR7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007;25(15):1960\u20136.","journal-title":"J Clin Oncol"},{"issue":"13","key":"6636_CR8","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"6636_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/gutjnl-2012-302759","volume":"62","author":"V Heinemann","year":"2013","unstructured":"Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, M\u00e4rten A, Winkelmann C, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the \u2018Arbeitsgemeinschaft Internistische Onkologie\u2019 (AIO-PK0104). Gut. 2013;62(5):751\u20139.","journal-title":"Gut"},{"key":"6636_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2016.12.032","volume":"75","author":"A Irigoyen","year":"2017","unstructured":"Irigoyen A, Gallego J, Guillen Ponce C, Vera R, Iranzo V, Ales I, et al. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: efficacy and safety results of a phase IIb randomised study from the Spanish TTD collaborative group. Eur J Cancer. 2017;75:73\u201382.","journal-title":"Eur J Cancer"},{"key":"6636_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2018.02.008","volume":"94","author":"M Haas","year":"2018","unstructured":"Haas M, Siveke JT, Schenk M, Lerch MM, Caca K, Freiberg-Richter J, et al. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: a prospective phase II study of the \u2018Arbeitsgemeinschaft Internistische Onkologie\u2019. Eur J Cancer. 2018;94:95\u2013103.","journal-title":"Eur J Cancer"},{"issue":"19","key":"6636_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"18","key":"6636_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"7","key":"6636_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14740338.2016.1177510","volume":"15","author":"CB Westphalen","year":"2016","unstructured":"Westphalen CB, Kruger S, Haas M, Heinemann V, Boeck S. Safety of palliative chemotherapy in advanced pancreatic cancer. Expert Opin Drug Saf. 2016;15(7):947\u201354.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"6636_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.hpb.2017.06.010","volume":"19","author":"LB van Rijssen","year":"2017","unstructured":"van Rijssen LB, Koerkamp BG, Zwart MJ, Bonsing BA, Bosscha K, van Dam RM, et al. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch pancreatic Cancer audit. HPB (Oxford). 2017;19(10):919\u201326.","journal-title":"HPB (Oxford)"},{"issue":"10018","key":"6636_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"issue":"23","key":"6636_CR17","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423\u20139.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6636-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:16:41Z","timestamp":1614039401000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6636-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6636"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6636-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"19 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethical committee of the Faculty of Medicine of the University in Cologne, Germany, on 02 March 2012 (reference number 11\u2013334) and was conducted according to the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization (now: International Council for Harmonization). All patients gave signed, informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CBW reports personal fees from Roche, Celgene, RedHill and Ipsen; grants from Roche, outside the submitted work. TK has nothing to disclose. BG reports research funding from Sirtex; speaker\u2019s honoraria from Sirtex, Roche, Amgen, Pfizer, Celgene, Merck and Novartis; advisory board memberships at Sirtex, Roche and Amgen; travel grants from Merck, Amgen, Celgene and B. Braun Travacare. LH has nothing to disclose. MF has nothing to disclose. PM has nothing to disclose. MR has nothing to disclose. FK reports personal fees from Sirtex and Shire, outside the submitted work. VH reports grants, personal fees and non-financial support from Merck KGaA, Roche, Amgen, Sirtex and Bayer; grants and personal fees from Celgene and Boehringer Ingelheim; personal fees and non-financial support from Sanofi; personal fees from Lilly, Baxalta, Taiho, Merrimack and Servier; grants from Shire and Pfizer, outside the submitted work. AB reports employment at Roche. DTW reports consulting fees from Bayer Health Pharma, BMS, Celgene, Novartis, Roche Pharma AG, Shire Baxelta and Sirtex; presenter fees from Bayer Health Pharma, BMS, Celgene, Novartis, Shire Baxelta and Sirtex; research grants from Roche Pharma AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}